Апо-Клоразепат

Quick links

Choose a section

Quick links to important sections

Advertisements

Апо-Клоразепат

Advertisements
Advertisements
Advertisements

Overview of Апо-Клоразепат

Quick Facts

Property Description
Active ingredient Dipotassium Clorazepate
Form Tablets or Capsules (Oral dosage form)
Pharmacological class Benzodiazepine, Central Nervous System (CNS) Depressant
General Purpose Mitigation of over-excitability and stabilization of neurological activity
Origin Synthetic

What Type of Medicine is Апо-Клоразепат? (Identity and Classification)

Апо-Клоразепат is a pharmaceutical product containing the active ingredient Dipotassium Clorazepate, which is formally classified as a Benzodiazepine and a Central Nervous System (CNS) Depressant. This compound is a synthetic substance manufactured for oral administration, typically presented as a solid oral dosage form. This classification is clinically recognized for its potent effects on the central nervous system, where it facilitates and amplifies inhibitory signals across the brain. This medication is typically reserved for adult patient groups, or, in limited cases, older children, reflecting the need for cautious management inherent to this pharmacological class.

Understanding the Active Component: Dipotassium Clorazepate (Composition and Form)

The therapeutic action of Апо-Клоразепат relies entirely upon its active ingredient Dipotassium Clorazepate, which functions uniquely as a prodrug. This mechanism means the administered compound is biologically inert until it undergoes rapid metabolic conversion into its true functional agent, Nordazepam (or Desmethyldiazepam). This conversion process is essential for realizing its therapeutic effects, a characteristic distinguishing it within the benzodiazepine family. The common trade names for this formulation, such as Tranxene, further indicate that Dipotassium Clorazepate is widely used as a single-ingredient product for its specific mode of action.

What is the General Purpose of Апо-Клоразепат? (Core Benefit)

The fundamental purpose of this medication is to enhance the effects of Gamma-aminobutyric acid (GABA), the brain's main inhibitory neurotransmitter, thereby creating a generalized reduction in excessive neurological excitability. This CNS depressant activity establishes its general dual therapeutic roles: serving as an anxiolytic to mitigate states of high agitation and acting as an anticonvulsant to stabilize erratic electrical activity. A typical neutral use scenario for which the compound is clinically studied involves stabilizing the neurological state of patients experiencing acute withdrawal symptoms.

Advertisements

What side effects are possible with Апо-Клоразепат?

Possible Side Effects and Safety Information

Apo-Clorazepate (clorazepate dipotassium) is a Central Nervous System (CNS) depressant classified as a DEA Schedule IV controlled substance due to its risks of abuse, misuse, addiction, dependence, and withdrawal.

Regulatory warnings highlight the danger of profound sedation, respiratory depression, coma, and death when this medication is used concomitantly with opioids or other CNS depressants, including alcohol. Its prolonged use carries a risk of physical and psychological dependence, and abrupt discontinuation may precipitate a severe, potentially life-threatening withdrawal syndrome that can include convulsions, tremor, and delirium.

Documented Adverse Reactions

Classification Examples of Reactions
Common Drowsiness, dizziness, dry mouth, blurred vision, headache, and various gastrointestinal complaints.
Clinically Significant Paradoxical reactions (e.g., excitement, hostility, agitation), suicidal thoughts or behavior (risk associated with antiepileptic drug class), mental confusion, and ataxia.

Safety Considerations

Contraindications include documented hypersensitivity to benzodiazepines and narrow-angle glaucoma. The drug is generally not recommended for use in patients less than 9 years of age due to insufficient clinical data. Older adults may be more susceptible to adverse effects like confusion and unsteadiness. Caution is required in patients with a history of drug or alcohol abuse, depression, or hepatic/renal impairment. Patients must be advised against engaging in hazardous activities, such as driving or operating heavy machinery, until the drug’s effects on psychomotor performance are known. For patients on long-term therapy, periodic blood counts and liver function tests are recommended.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Апо-Клоразепат (Dipotassium Clorazepate) is officially documented in regulatory sources as an exaggeration of its central nervous system (CNS) depressant effects. Manifestations officially listed include profound somnolence (drowsiness), significant confusion, slurred speech, lethargy, ataxia (loss of coordination), and diminished reflexes.

The official labeling identifies severe risks, primarily involving the vital systems. These include potentially life-threatening outcomes such as profound sedation, respiratory depression, and severe hypotension, which may escalate to circulatory shock or coma. Regulatory warnings strongly emphasize that the co-ingestion of this medicine with other CNS depressants, such as alcohol or opioid medications, drastically increases the overall risk of these severe events, including potential fatal outcomes.

Immediate medical attention must be sought if an overdose is suspected. Official regulatory guidance explicitly states that emergency services must be contacted if the affected person has collapsed, experienced a seizure, is having significant trouble breathing, or cannot be awakened.

Management procedures officially described are symptomatic and supportive, focusing on the maintenance of cardiovascular and respiratory function. This requires continuous monitoring of vital signs in a hospital setting. The benzodiazepine antagonist Flumazenil is documented as a procedural option for reversing the sedative effects, though its administration is subject to regulatory warnings regarding use in dependent patients. Elderly patients are also noted in official documents to have an increased susceptibility to prolonged CNS depressant effects.

Advertisements

Therapeutic Uses of Апо-Клоразепат

The primary therapeutic utility of Апо-Клоразепат lies in providing symptomatic relief across three distinct clinical domains, all characterized by underlying neurological hyperexcitability. This medication is commonly used to help with conditions presenting with heightened symptoms, including support in contexts involving acute or temporary symptomatic periods for severe anxiety symptoms, acting as an adjunctive therapy for managing partial seizures (focal seizures), and providing symptomatic relief in acute alcohol withdrawal syndrome.

“The medication may be part of symptomatic management in contexts where temporary neurological stabilization is needed.”


Management of Severe, Disabling Anxiety

This medication is considered relevant in contexts involving support in acute or temporary symptomatic periods for severe anxiety symptoms that are intense and significantly interfere with daily functioning. It may be applied to help address symptom clusters involving acute apprehension, debilitating tension, and high emotional agitation. The key benefit is offering supportive relief that helps patients cope more steadily during periods of heightened distress.

Quick Fact: Relevant for Symptoms of Heightened Physiological Activity This medication is commonly used when symptoms create noticeable physiological strain and heightened discomfort, and may be part of symptomatic management.


Adjunctive Therapy for Partial Seizures

Апо-Клоразепат is commonly used as an add-on (adjunctive) therapy for patients, including older children (typically ge 9 years), who are managing partial seizures (focal seizures). This use supports the overall antiepileptic regimen by assisting in the stabilization of erratic electrical activity in the brain, which may assist with maintaining functional stability during symptomatic periods.


Symptomatic Relief in Acute Alcohol Withdrawal

The drug is relevant for easing symptoms associated with acute alcohol withdrawal syndrome. It addresses the pronounced and challenging manifestations of this phase, such as extreme physical and mental overstimulation and agitation. The therapeutic benefit may assist with achieving necessary symptom stabilization during the critical detoxification period, which supports the patient during difficult episodes by easing distress.

Advertisements

Eligibility and Restrictions for Use

The eligibility for using Апо-Клоразепат is strictly defined by regulatory authorities based on age, pre-existing conditions, and physiological status.

Populations for Whom Use is Prohibited (Contraindications)

Condition/Status Restriction Type
Known Hypersensitivity to the drug or any benzodiazepine Absolute Prohibition
Acute Narrow-Angle Glaucoma Absolute Prohibition
Myasthenia Gravis Absolute Prohibition

Conditional and Age-Based Restrictions

  • Pediatric Use: The medication is not recommended for use in patients less than 9 years of age due to the lack of sufficient clinical experience and established safety. Use is established for children ge 9 years old only for certain seizure conditions.
  • Older Adults (ge 65 years): Caution is required, and use should be initiated with a small initial dose due to the possibility of greater sensitivity.
  • Hepatic or Renal Impairment: Use requires caution and observation of usual precautions. Patients with Severe Hepatic Insufficiency are generally contraindicated.
  • Pregnancy and Lactation: Use should almost always be avoided during the first trimester of pregnancy. The drug is not recommended for use by nursing mothers, as the active metabolite is known to be excreted in breast milk.
  • Psychiatric Status: Not recommended for use in patients with depressive neuroses or psychotic reactions.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Dipotassium Clorazepate identifies several drug classes and substances that may interact, primarily through additive pharmacodynamic effects on the central nervous system (CNS).

Pharmacodynamic and Exposure Interactions

Interacting Class/Substance Official Interaction Description
Opioids and other CNS Depressants (e.g., Barbiturates, Hypnotic Medications) Co-administration is documented to increase the risk of profound sedation, respiratory depression, coma, and death due to combined CNS depressant activity.
MAOIs and Other Antidepressants The actions of the benzodiazepine may be potentiated (increased) by these medications.

Substance and Population Considerations

Context Official Regulatory Statement
Alcohol (Ethanol) The CNS depressant effects of alcohol are officially stated to be increased.
Elderly Population Slower elimination of the active metabolite (Nordiazepam) may lead to drug accumulation and higher exposure.
Food/Supplements No specific, formal interactions are documented in core regulatory labeling.

No specific mandatory timing separation rules are documented. The drug's interaction profile is defined by the high-level risk of additive CNS depression and the potential for potentiated exposure effects when combined with various psychotropic agents, as stated in authoritative government labeling.

Advertisements

Mechanism of Action

Apo-Clorazepate functions as a positive allosteric modulator of the GABA A receptor complex. It is a pro-drug that is metabolized primarily in the acidic environment of the stomach to its active metabolite, nordiazepam. This active form binds to a specific modulatory site on the GABA A receptor, most commonly located at the interface of the a and y subunits.

Binding induces a conformational change in the receptor protein, which increases the receptor's affinity for the inhibitory neurotransmitter gamma-aminobutyric acid ( GABA). The enhanced GABA binding facilitates the frequency of opening of the associated chloride ion channel, resulting in greater transmembrane flux of Cl^- ions. This influx leads to hyperpolarization of the postsynaptic membrane. This mechanism alters the overall excitability of neuronal membranes, resulting in a decreased frequency of action potential generation and modulation of sustained overexcitation.

Advertisements

Dosage and Administration Information

The medicine containing Dipotassium Clorazepate is officially approved for oral administration in specific tablet and capsule strengths, including 3.75 mg, 7.5 mg, and 15 mg. The correct administration pattern is determined by the approved condition being managed. For managing symptoms of anxiety, the regimen typically begins with a daily dose of 15 mg. This initial dose may be taken as a single administration at bedtime or divided into multiple 7.5 mg doses throughout the day. The dose is then maintained within the range of 15 mg to 60 mg daily, and use for this purpose is generally limited to short courses of four months or less.

When used as an adjunctive therapy for partial seizures, the medication is started at 7.5 mg three times daily, with the option to gradually increase the dose up to a maximum recommended daily intake of 90 mg. In the context of acute alcohol withdrawal, administration follows a short, defined schedule involving a rapidly decreasing dose over approximately four days, starting with an initial dose of 30 mg and not exceeding 90 mg on the first day.

Official usage instructions include specific rules for certain patient populations. Older or debilitated adults should begin with a lower initial daily dose, typically 7.5 mg to 15 mg. For pediatric patients 9 to 12 years of age receiving adjunctive seizure therapy, the maximum recommended daily dose is 60 mg. The medication may be taken with food. A critical procedural condition is the requirement for gradual dose reduction when discontinuing the medicine after extended use; abrupt cessation is not part of the labeled protocol.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Апо-Клоразепат


Evidence for Use in Managing Anxiety Symptoms

Research has studied Dipotassium Clorazepate in double-blind, placebo-controlled clinical trials involving adults with anxiety. These studies primarily examine outcomes related to symptom intensity and variability over short durations. A primary gap noted in the research is the lack of systematic clinical studies to assess the measured outcomes and patterns of use extending beyond approximately four months. Therefore, evidence is not well established for the long-term management of sustained anxiety.


Evidence for Use as Adjunctive Therapy for Partial Seizures

This medication was evaluated in studies as an add-on treatment for partial seizures, with research involving both adults and children aged nine years and older. The studies monitored key outcomes related to measurements of seizure frequency and overall seizure status. While long-term observational data was collected to track continued therapeutic activity in the epileptic patient population, data remains insufficient for pediatric patients under the age of nine years. Pooled data from the anti-epileptic drug (AED) class suggest that certain neurological effects, such as suicidal thoughts or behavior, were observed in some studies of the class and findings indicate patterns related to this observation.


Evidence for Use in Acute Alcohol Withdrawal

The medication was studied for use during the acute alcohol withdrawal syndrome via short-term prophylactic treatment trials in adult inpatients. Outcomes examined focused on the prevention and tracking of severe physical withdrawal signs and patient status over short regimens, such as defined five-day treatment schedules. Evidence is limited strictly to this acute, short-duration phase, and comparative evidence for the medication's role in the long-term management or prevention of chronic substance use disorders is lacking.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Апо-Клоразепат (FAQ)

Q: What is the main reason a doctor would prescribe Апо-Клоразепат?

The primary uses described in official sources are the short-term management of anxiety, the adjunctive (add-on) treatment of partial seizures, and the management of acute alcohol withdrawal syndrome.

Q: Is it true that Апо-Клоразепат is a benzodiazepine?

Yes, official product information confirms that the medication is pharmacologically classified as a benzodiazepine.

Q: Is Апо-Клоразепат the same type of medicine as Valium?

According to regulatory documents, both medications are classified pharmacologically as benzodiazepines. Furthermore, this drug is a prodrug that is converted to the active substance nordiazepam, which is also a substance produced when the body processes Valium (diazepam).

Q: How quickly does Апо-Клоразепат start to work?

Clinical pharmacology information indicates that the drug’s active substance, nordiazepam, reaches its peak levels in the bloodstream shortly after the medication is taken orally, typically between 30 minutes and 2 hours.

Q: How long does the effect of Апо-Клоразепат typically last?

Studies show that the active substance has a long half-life, meaning it takes approximately 40 to 50 hours for half of it to be eliminated from the bloodstream. This duration classifies the medication as long-acting.

Q: What are the most commonly mentioned side effects of Апо-Клоразепат?

Common adverse reactions reported in official documents include drowsiness, dizziness, upset stomach, blurred vision, and dry mouth. These are typically the most frequently mentioned effects.

Q: Does Апо-Клоразепат cause drowsiness or fatigue?

Yes, drowsiness and fatigue are listed in the official documents as commonly reported side effects. These effects are expected due to the drug's action on the central nervous system.

Q: Can Апо-Клоразепат affect my driving ability?

Official warnings advise that because the medication has central nervous system (CNS) depressant effects, patients should be aware of impaired alertness when operating a motor vehicle or machinery.

Q: Are there any common foods or drinks that should be avoided with Апо-Клоразепат?

Official warnings state that simultaneous use with alcohol should be avoided, as this combination may significantly increase the depressant effects of the medication. Official documents generally do not list specific food restrictions.

Q: What are the major drug categories that interact with Апо-Клоразепат?

The major drug categories officially warned against combining with this medication include opioids and other Central Nervous System (CNS) depressant drugs.

Q: Can older adults use Апо-Клоразепат?

The medication can be used in older adults, but regulatory documents advise that the initial dose should be low. Caution is advised due to the potential for excessive sedation, dizziness, and lack of coordination.

Q: Is Апо-Клоразепат suitable for children?

Due to a lack of sufficient clinical experience and safety data, the medication is officially not recommended for use in patients under 9 years of age.

Q: Does taking Апо-Клоразепат mean I can’t drink alcohol at all?

Official warnings advise that simultaneous use with alcohol should be avoided. This is because alcohol may significantly increase the depressant effects of the medication, which could lead to severe outcomes.

Q: Are there any known issues with using Апо-Клоразепат long-term?

Official product information notes that the effectiveness in managing anxiety for periods longer than four months has not been systematically studied. It is also stated that continued use exposes users to risks of abuse, dependence, and withdrawal.

Q: What is the regulatory status of Апо-Клоразепат?

According to regulatory authorities in the United States, this medication is classified as a Schedule IV (C-IV) federally controlled substance. This means its distribution and prescribing are regulated by law.

Q: What should I know about the safety profile of Апо-Клоразепат?

The official safety profile includes important warnings regarding the risks of physical dependence, abuse, withdrawal, and severe sedation. Patients are also alerted to common side effects such as drowsiness and dizziness.

Q: Can Апо-Клоразепат cause a change in mood?

Official labels state that there is a need to be alert for the emergence or worsening of signs of depression and unusual changes in mood or behavior.

Q: Is it possible to become dependent on Апо-Клоразепат?

Official warnings state that the continued use of this drug may lead to clinically significant physical dependence. The risk is typically associated with higher doses or longer duration of use.

Q: Are there specific medical conditions that prevent someone from using Апо-Клоразепат?

Yes, regulatory documents list specific contraindications (conditions where the drug should not be used). These include known hypersensitivity to the drug and the condition known as acute narrow angle glaucoma.

Q: Is Апо-Клоразепат an addictive medicine?

Official information warns that the use of this drug exposes users to risks of abuse, misuse, and addiction. Addiction is a potential safety concern associated with benzodiazepines.

Q: What is the classification of Апо-Клоразепат under controlled substances laws?

The medication is regulated as a Schedule IV (C-IV) controlled substance under federal laws in the United States.

Q: How is Апо-Клоразепат eliminated from the body?

According to clinical pharmacology, the drug is metabolized, or processed, in the liver into its active substance, nordiazepam. This active substance and its final byproducts are then excreted primarily in the urine.

Q: Do women who are breastfeeding have restrictions on using Апо-Клоразепат?

Official guidance indicates that the drug is not recommended for use by nursing mothers. This restriction is in place because the active substance is known to be excreted into human breast milk.

Q: What research is available on the effectiveness of Апо-Клоразепат?

Research evidence is established in official documents for the three main approved indications: management of anxiety, adjunctive therapy for partial seizures, and the treatment of acute alcohol withdrawal.

Q: Is it normal to feel a little dizzy after taking Апо-Клоразепат?

Yes, dizziness is listed as a common side effect in the official adverse reactions section.

Q: Does Апо-Клоразепат have a 'half-life' and what does that mean?

Yes, the drug's active substance has an extended half-life, typically around 40 to 50 hours. The half-life refers to the amount of time required for the concentration of the medication in the body to be reduced by half.

Q: Why are there official warnings about combining Апо-Клоразепат with opioids?

Regulatory authorities have issued an official Boxed Warning for this combination. This is because combining the two types of medication may result in profound sedation, severe respiratory depression, coma, and even death.

Q: Can people with liver problems use Апо-Клоразепат?

Official guidance states that caution is advised when the drug is used in patients with impaired hepatic (liver) function, as the drug is processed by the liver.

Q: How does the official guidance describe stopping the use of Апо-Клоразепат?

Official guidance notes that discontinuation or dosage reduction should involve a gradual taper to minimize the risk of severe withdrawal reactions. Abrupt cessation is strongly advised against by regulatory documents.

Q: Does the efficacy of Апо-Клоразепат decrease over time?

Official warnings note that tolerance can develop with continued use. This means that the body may adapt to the drug, leading to a potential decrease in its therapeutic effects over time.

Q: Is there a risk of withdrawal if Апо-Клоразепат is stopped suddenly?

Yes, official warnings state that abrupt discontinuation or rapid dosage reduction after continued use carries a risk of acute, potentially life-threatening withdrawal reactions, including seizures.

Q: Are there any requirements for monitoring while someone is using Апо-Клоразепат?

Regulatory guidance states that for patients taking the medication for prolonged periods, periodic monitoring is indicated. This typically includes monitoring of blood counts and liver function tests.

Q: Is it possible to have an allergic reaction to Апо-Клоразепат?

The medication is contraindicated (should not be used) in patients with a known hypersensitivity to the drug. A hypersensitivity reaction includes severe allergic reactions.

Q: How does the drug work inside the body to help with its primary purpose?

The medication is a prodrug that is converted to the active substance nordiazepam. This substance acts by enhancing the inhibitory effects of a natural chemical called GABA in the central nervous system.

Q: Are there different names or brands for the same drug as Апо-Клоразепат?

The chemical name for the active substance is Dipotassium Clorazepate. One brand name under which this medication is marketed is Tranxene.

Q: Can people with kidney issues use Апо-Клоразепат?

Official guidance states that caution is advised when the drug is used in patients with impaired renal (kidney) function.

Q: What did the key clinical trials for Апо-Клоразепат focus on?

Key clinical trials focused primarily on establishing the efficacy and safety profile for the three approved indications: anxiety, partial seizures, and acute alcohol withdrawal.

Q: Is a prescription required for Апо-Клоразепат?

Yes, according to controlled substance laws and regulatory status, this medication is available by prescription only.

Q: Why is it important to know who cannot use Апо-Клоразепат?

It is important because official guidance lists conditions where the drug should not be used (contraindications), such as acute narrow angle glaucoma, to prevent serious adverse reactions and potential harm.

Q: What is the definition of the 'main uses' for Апо-Клоразепат?

The main prescribed applications listed in regulatory documents are the management of anxiety disorders, adjunctive therapy for partial seizures, and the short-term treatment of acute alcohol withdrawal.

Q: Is Апо-Клоразепат used to help with sleep?

While not officially indicated as a sleep aid, the medication has general depressant effects on the central nervous system (CNS). Dosing instructions for anxiety often allow a single administration at bedtime, which suggests utilizing its sedative properties.

Q: Do studies support the use of Апо-Клоразепат for anxiety?

According to the official product information, the medication is indicated for the management of anxiety disorders. It is also used for the short-term relief of general anxiety symptoms.

Q: Has Апо-Клоразепат been studied for use in chronic conditions?

Yes, studies support its use as an adjunctive (add-on) therapy in the management of partial seizures, which is a condition often managed over an extended period.

Advertisements

How should Апо-Клоразепат be stored and disposed of?

How to Store and Dispose of Апо-Клоразепат?

The official storage and disposal guidelines for Апо-Клоразепат (Dipotassium Clorazepate) are governed by regulatory requirements to maintain product quality and safety.

Storage Requirements

Condition Regulatory Statement
Temperature Store at controlled room temperature (20^circC to 25^circC) and keep away from excess heat and freezing.
Protection Keep the medication in its original, tightly closed container and protect from light and moisture. Do not store in the bathroom.
Security As a controlled substance, the product must be stored in a secure location and kept out of the sight and reach of children.

Disposal Instructions

Official disposal rules recommend returning unused or expired medication to a pharmacy or approved drug take-back program. The product must not be flushed down the toilet or disposed of in any wastewater system, as it is not on the official flush list. The disposal of outdated medication should be performed promptly.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Апо-Клоразепат found in:

A-Z Index: